# Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

> **NCT05286320** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma
- Pembrolizumab
- Lenvatinib
- Stereotactic Body Radiotherapy

## Interventions

- **DRUG:** Lenvatinib/Pembrolizumab plus SBRT combinations

## Key facts

- **NCT ID:** NCT05286320
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286320, "Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05286320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*